PA
AXSM icon

Parallel Advisors’s Axsome Therapeutics AXSM Stock Holding History

Parallel Advisors’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$52.9K Buy
216
+199
+1,171% +$43.2K ﹤0.01% 2102
2026
Q1 		$2.87K Buy
17
+2
+13% +$345 ﹤0.01% 3249
2025
Q4 		$2.74K Buy
15
+3
+25% +$419 ﹤0.01% 3048
2025
Q3 		$1.46K Hold
12
– – ﹤0.01% 3129
2025
Q2 		$1.25K Sell
12
-3
-20% -$318 ﹤0.01% 3150
2025
Q1 		$1.75K Buy
15
+3
+25% +$342 ﹤0.01% 3010
2024
Q4 		$1.01K Hold
12
– – ﹤0.01% 3108
2024
Q3 		$1.08K Hold
12
– – ﹤0.01% 3014
2024
Q2 		$966 Buy
+12
New +$888 ﹤0.01% 2967
2022
Q1 		– Sell
-92
Closed -$3K – 2967
2021
Q4 		$3K Buy
92
+15
+19% +$552 ﹤0.01% 2551
2021
Q3 		$3K Buy
77
+60
+353% +$2.34K ﹤0.01% 2541
2021
Q2 		$1K Hold
17
– – ﹤0.01% 2691
2021
Q1 		$1K Buy
+17
New +$1.2K ﹤0.01% 2579

Other funds holding AXSM

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Parallel Advisors's AXSM Position: Q2 2026 in Review

Parallel Advisors increased its Axsome Therapeutics (AXSM) stake by 1,171% in Q2 2026, buying an estimated $43.2K and bringing the position to 216 shares worth $52.9K. The position accounts for ﹤0.01% of the portfolio, ranked #2102.

Parallel Advisors first reported a position in AXSM in Q1 2021 and has held it in 13 quarters since. 506 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

  • Parallel Advisors held 216 shares of Axsome Therapeutics worth $52.9K as of Q2 2026.
  • Parallel Advisors bought 199 Axsome Therapeutics shares in Q2 2026, an estimated $43.2K.
  • Axsome Therapeutics made up ﹤0.01% of Parallel Advisors's portfolio in Q2 2026, its #2102 holding.
  • Parallel Advisors first reported a position in Axsome Therapeutics in Q1 2021 and has held it in 13 quarters since.
  • 506 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on Parallel Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.